Published online before print October 30, 2006, doi: 10.1161/01.HYP.0000249904.93940.7a
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2007;49:113.)
© 2007 American Heart Association, Inc.
Original Articles |
Polymorphic Variation in the 11ß-Hydroxylase Gene Associates With Reduced 11-Hydroxylase Efficiency
From the British Heart Foundation Glasgow Cardiovascular Research Centre (M.B., S.M.M., E.C.F., C.D.H., D.M.W., N.J.R.B., M.C.I., R.F., A.F.D., J.M.C.C., E.D.), University of Glasgow, Glasgow; Clinical Pharmacology and the Cambridge Institute of Medical Research (M.B., D.C.), University of Cambridge, Addenbrooke’s Hospital, Cambridge; the Department of Cardiovascular Sciences (N.J.S.), University of Leicester, Glenfield Hospital, Leicester; Clinical Pharmacology and Barts and the London Genome Centre (M.C., P.B.M.), William Harvey Research Institute Barts and the London School of Medicine, Charterhouse Square, London; the Nuffield Department of Clinical Medicine and Department of Cardiovascular Medicine (M.F.), University of Oxford, Wellcome Trust Centre for Human Genetics, Oxford; and Medicine and Therapeutics (J.W.), Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
Correspondence to John M.C. Connell, Medical Research Council Blood Pressure Group, Division of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, 126 University Place, Glasgow G12 8TA, United Kingdom. E-mail J.Connell{at}clinmed.gla.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
The –344 C/T and intron 2 conversion variants in the CYP11B2 gene, encoding aldosterone synthase, have been associated with markers of impaired 11ß-hydroxylase activity. We hypothesize that this association is because of variations in the adjacent 11ß-hydroxylase gene (CYP11B1) and arises through linkage disequilibrium between CYP11B1 and CYP11B2. The pattern of variation across the entire CYP11B locus was determined by sequencing 26 normotensive subjects stratified by and homozygous for the –344 and intron conversion variants. Eighty-three variants associated with –344 and intron conversion were identified. Haplotype analysis revealed 4 common haplotypes, accounting for 68% of chromosomes, confirming strong linkage disequilibrium across the region. Two novel CYP11B1 polymorphisms upstream of the coding region (–1889 G/T and –1859 A/G) were identified as contributing to the common haplotypes. Given the potential for such mutations to affect transcriptional regulation of CYP11B1, these were analyzed further. A total of 512 hypertensive subjects from the British Genetics of Hypertension Study population were genotyped for these polymorphisms. A significant association was identified between the –1889 polymorphism and urinary tetrahydrodeoxycortisol/total cortisol metabolite ratio, indicating reduced 11ß-hydroxylase efficiency. A similar pattern was observed for the –1859 polymorphism, but this did not achieve statistical significance. Functional studies in vitro using luciferase reporter gene constructs show that these polymorphisms significantly alter the transcriptional response of CYP11B1 to stimulation by adrenocorticotropic hormone or forskolin. This study strongly suggests that the impaired 11ß-hydroxylase efficiency associated previously with the CYP11B2 –344 and intron conversion variants is because of linkage with these newly identified polymorphisms in CYP11B1.
Key Words: hypertension • aldosterone synthase • 11ß-hydroxylase • polymorphisms • transcriptional regulation
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The mineralocorticoid hormone aldosterone plays an important role in blood pressure homeostasis. In the Framingham population, plasma aldosterone levels in the top quartile of the normal distribution predicted subsequent rise in blood pressure and future development of hypertension.1 Furthermore,
15% of unselected patients with hypertension have a raised aldosterone/renin ratio, suggesting that altered regulation of aldosterone synthesis or release may be a common factor in essential hypertension.2–6
The late stages in aldosterone synthesis that occur in the zona glomerulosa of the adrenal cortex are key in the control of production of the hormone. The 3 terminal steps are a sequential 11ß-hydroxylation, 18-hydroxylation, and 18-oxidation of the precursor 11-deoxycorticosterone, all catalyzed by the enzyme aldosterone synthase. This enzyme is encoded by the CYP11B2 gene, the major regulator of which is angiotensin II. In the zona fasciculata, cortisol is synthesized by a similar pathway, but the final stage is an 11ß-hydroxylation of 11-deoxycortisol (S) by the highly homologous enzyme 11ß-hydroxylase. The CYP11B1 gene, which is controlled by adrenocorticotropic hormone (corticotropin [ACTH]), encodes 11ß-hydroxylase. CYP11B2 and CYP11B1 are situated 
40 kb apart on chromosome 8 in humans. They share 95% sequence similarity, with the main differences being in the 5' regions that are responsible for the differences in their transcriptional regulation.7
Two common variants have been described previously in the CYP11B2 gene.8 The first is a single nucleotide substitution from cytosine to thymidine in the 5' promoter region (–344 C/T), which disrupts a putative binding site for the steroidogenic factor 1. The second is an intron conversion in intron 2. This variant exists in 2 alternate forms, either the wild-type (Wt) or the conversion (Conv), where part of intron 2 is replaced by the corresponding intron of the adjacent CYP11B1 gene. These variants are in tight linkage disequilibrium (LD) so that the common haplotypes are T/Conv (38%), C/Wt (45%), and T/Wt (16%).9 The T allele at –344 and the Conv allele in intron 2 have been associated previously with hypertension, hypertension with a raised aldosterone/renin ratio, as well as increased levels of aldosterone.9–12 However, it should be mentioned that these are not consistent findings, with some studies not seeing any association and others observing an association with the C allele.13–16
Interestingly, one consistent reported phenotypic association with the T/Conv haplotype is impaired 11ß-hydroxylase efficiency, indicated by raised ACTH-stimulated levels of the 11-deoxysteroids, 11-deoxycorticosterone and S (which are themselves substrates for the 11ß-hydroxylase enzyme).17,18 The molecular mechanism that results in this phenotype is unclear; in vitro reporter gene studies of the –344 C/T single nucleotide polymorphism (SNP) show no detectable effect on gene transcription, suggesting that this is not the causative variant.19 Ganapathipillai et al20 reported that the same biochemical phenotype was associated with a CYP11B1/B2 haplotype that included the –344 T variant, and it is likely that the –344 C/T SNP is in LD with causative variants in CYP11B1 that could account for this phenotype. We have reported previously that a SNP in exon 1 (Leu75Leu) of CYP11B1 was strongly associated with the phenotype,21 but this conservative polymorphism cannot, itself, account for the biochemical change. Accordingly, the aims of the present study were to investigate in detail the pattern of variation across the CYP11B1/CYP11B2 locus to define the precise LD with the –344 C/T and intron Conv variants. Investigation of the association of 11ß-hydroxylase efficiency with novel CYP11B1 SNPs and also analysis of their effects in vitro was performed to determine the genetic variation responsible for the observed impaired 11ß-hydroxylation.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Subjects
Normal subjects were selected from a World Health Organization survey of cardiovascular risk factors (multinational MONItoring of trends and determinants in CArdiovascular disease [MONICA] IV), which was a random sample of the North Glasgow, Scotland, population.22 Subjects were aged 36 to 57 years and were normotensive with a fairly narrow blood pressure range (109 to 142 mm Hg systolic and 66 to 90 mm Hg diastolic). Full demographic characteristics of the population and details of blood pressure measurements have been published elsewhere.22 These subjects had already been genotyped for the –344 C/T and intron Conv variants. Twenty-six subjects were selected for genetic analysis: TT/ConvConv (n=10), CC/WtWt (n=10), and TT/WtWt (n=6).
A large hypertensive study population was derived from the Medical Research Council British Genetics of Hypertension (BRIGHT) Study. The BRIGHT Study is a large multicenter investigation into the genetic basis of hypertension, composed of >2500 affected sibling pairs. Hypertensive subjects were recruited from primary care with entry to the study being dependent on a pretreatment blood pressure of >145/95 mm Hg (mean of 3 readings). Details of the methods for blood pressure measurements and other demographic characteristics can be found at www.brightstudy.ac.uk. It was aimed to exclude subjects with a body mass index >30. Full details of the recruitment strategy have been published elsewhere.23 For the present investigation, we selected a random subgroup of 512 unrelated hypertensive subjects. Full demographic information (as medians and interquartile ranges) on the subjects included is shown in Table 1.
|
Ethical approval for the study was granted by the local ethics committees of the partner institutes, and fully informed written consent from all of the participants was obtained. All of the procedures were in accordance with institutional guidelines.
Polymorphism Detection
PCR
The nucleotide sequences for human CYP11B1 (accession numbers: D10169, M32863, X85218, M32878, and M32879) and CYP11B2 (accession numbers: D10170, D13752, and M32881) were obtained from the Entrez Nucleotide database. All of the PCRs were performed using Expand High Fidelity PCR system with proofreading capabilities, according to the manufacturer’s protocol (Roche Diagnostics). The amplification of CYP11B1 was performed as 2 reactions: from –2 kb of the 5' region to the end of exon 9 (7.5 kb) and from the 3' region, downstream of the coding region (750 bp). The amplification of CYP11B2 was split into 3 separate PCRs: (1) from the 5' region to intron 4 (5 kb); (2) from exon 5 to exon 9 (3 kb); and (3) the 3' region, downstream of the coding region (1.5 kb). The sequences of the primers (MWG-Biotech) used for these reactions is available in an online supplement at http://hyper. ahajournals.org.
Sequencing
Automated sequencing of the entire region was performed using the ABI Big Dye Terminator v3.1 Cycle Sequencing kit (PE Applied Biosystems) and the ABI3730 Sequencer.
Haplotype Analysis
A Bayesian statistical method implemented in PHASE version 2.1 was used to construct phased haplotypes from phase-unknown genotype data.24 LD between all of the possible pairs of loci was calculated using EM estimation of haplotype frequencies and LD calculation, available online at http://request.mdacc.tmc.edu/qhuang/Software/pub.htm.
Genotyping of BRIGHT Study for –1889 G/T and –1859 A/G
A subset of the BRIGHT Study population (n=512) was genotyped for the –1889 G/T and –1859 A/G SNPs using a nested PCR method to increase specificity, followed by sequencing. In both reactions, a heat-activated thermostart Taq polymerase (Abgene) was used. Please see the online supplement for the sequences of the primers used in both reactions.
Urinary Corticosteroid Metabolite Measurements
Urine samples (24-hour) were collected in plain plastic containers without preservative. Aliquots of urine were stored at –20°C. Excretion rates of steroid metabolites were measured by gas chromatography/mass spectrometry using the method of Shackleton25 with minor modifications. The ratio of tetrahydrodeoxycortisol (THS)/total cortisol (total F) was used as an index of 11ß-hydroxylase activity.
In Vitro Expression Studies
Site-Directed Mutagenesis
The 5' regulatory region (1937bp) of CYP11B1 was cloned into the pGL3 basic vector (Promega Corp). The CYP11B1 –1889 G/T and –1859 A/G SNPs were constructed in vitro using this pGL3/B1 5'regulatory region construct. Site-directed mutagenesis was performed using the Quick-Change site-directed mutagenesis kit (Stratagene Ltd) following the protocol described previously.26 Please see the online supplement for the sequences of the primers used. The entire insert in each case was sequenced to confirm the presence of the desired mutations and that no unwanted base changes had been incorporated.
Cell Culture and Transfection
Y-1 mouse adrenal cells (American Type Culture Collection) were cultured at 37°C in 5% CO2 in F-12K Nutrient Mixture, Kaighn’s Modification (GIBCO) supplemented with 15% horse serum (GIBCO), 2.5% fetal bovine serum (Sigma-Aldrich), and 1% penicillin/streptomycin (GIBCO). Cells were plated at 3.5x105 cells per well in 6-well plates and incubated for 24 hours before transfection. Transfection was carried out using 6 µL of Fugene (Roche Diagnostics) and 1 µg of Wt or mutant plasmid in MEM/Eagle’s medium(2 ml) for 42 hours. The pSV-ß-galactosidase control vector (0.04 µg; Promega Corp) was added as a marker of transfection efficiency. After transfection, the cells were treated with agonists (forskolin 10 µmol/L or ACTH 1 µmol/L) for 6 hours. The cells were then lysed and luciferase activity measured according to the manufacturer’s protocols (Promega Corp). Protein (BCA assay, Pierce Biotechnology) and ß-galactosidase activity (Promega Corp) measurements were used to determine cell number and transformation efficiency, and the luciferase results were corrected appropriately.
Statistics
A 
2 test was used to determine whether the allele frequencies of –1889 G/T and –1859 A/G within the BRIGHT subgroup were in Hardy-Weinberg equilibrium. Steroid excretion data did not follow a normal distribution and so were compared by nonparametric methods (Mann-Whitney test). The in vitro expression results for each construct were compared with the appropriate control using a 2-sample t test. In all instances, a P value of <0.05 was accepted as significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Polymorphism Detection
Twenty-six subjects, from the normotensive MONICA population, already genotyped and homozygous for –344 C/T and intron Conv variants (TT/ConvConv [n=10], CC/WtWt [n=10], and TT/WtWt [n=6]), were screened for polymorphisms. A total of 83 biallelic polymorphisms were identified across the entire CYP11B locus (44 631 bp) that showed association with –344 C/T and intron Conv variants in CYP11B2 (Figure 1). Of the 83 polymorphisms, 64 were located within the CYP11B2 gene, and 19 were located within the CYP11B1 gene. The polymorphisms were spread throughout the gene exons, introns, and the adjacent upstream and downstream regions, with the highest frequency being located in intronic regions.
|
CYP11B2 Polymorphisms
Sixty-four variants were identified in CYP11B2 that are in LD with the –344 C/T and intron Conv variants (Figure 1). Most of these changes were part of the intron Conv variant in intron 2. Of the remainder, 3 single base substitutions were found in exons 3 and 6. Two of these are synonymous changes with no effect on amino acid sequence: Phe168Phe and Arg374Arg. These mutations have been described previously by the National Center for Biotechnology Information, accessible on the dbSNP website (http://ncbi.nlm.nih.gov/SNP), with the identification numbers rs4546 and rs4538, respectively.
The third, at codon 173 (rs4539), does cause an amino acid change from Lys to Arg but has been shown to have no effect on aldosterone synthase activity in vitro.27–28 Seven single base substitutions were also identified within the 5' regions immediately upstream of the CYP11B2 gene.
CYP11B1 Polymorphisms
Nineteen variants were identified in CYP11B1 that show association with the –344 C/T and intron Conv variants in CYP11B2 (Figure 1). As with CYP11B2, most of these were within intronic regions (introns 2 through 6 and 8). Two SNPs that were identified in exons 1 (Leu75Leu) and 2 (Asp82Asp) have been described previously (National Center for Biotechnology Information rs6410 and rs5283, respectively). Two novel SNPs were identified within the 5'regulatory region at positions –1889 (G/T) and –1859 (A/G) upstream of the ATG start codon. These SNPs are in LD with the T/Conv haplotype in CYP11B2 (Figure 2).
|
Because of their potential to alter CYP11B1 gene transcription, the –1889 G/T and –1859 A/G SNPs were identified as key functional candidates to account for the impaired 11ß-hydroxylase efficiency associated previously with the –344 T and the intron 2 Conv alleles.
Haplotype Analysis
Haplotype analysis revealed 9 haplotypes that have frequencies >1% and describe 75% of chromosomes in the data set. Four of these common haplotypes each have a frequency of >5% and, in combination, account for 68% of chromosomes in the data set (Figure 2). These haplotypes are conserved across the entire region, confirming that there is strong LD across the locus, with a D' value of 0.75 to 1.0 and an r2 value of 0.5 to 1.0.
Genotyping of BRIGHT Study for –1889 G/T and –1859 A/G
To determine whether the –1889 G/T and –1859 A/G SNPs associate with 11ß-hydroxylase efficiency, their frequency and phenotypic associations were investigated in the hypertensive BRIGHT population.
Demographic Data for BRIGHT Subgroup
Blood pressure and other relevant demographic data are shown in Table 1; the population was significantly hypertensive but not significantly overweight. The only significant difference in characteristics of subject groups separated according to the –1889 (GG versus TT P=0.015) or –1859 (AA versus GG P=0.013) SNPs was with waist/hip ratio.
Genetic Analysis of CYP11B1
The frequencies of the –1889 and –1859 SNPs are illustrated in Table 2 (–1889 G: 0.53, T: 0.47; –1859 A: 0.5, G: 0.5). The alleles of both –1889 G/T and –1859 A/G were in Hardy-Weinberg equilibrium with 2 values of 0.91 and 0.82, respectively.
|
Association With THS/Total F Metabolites
The major urinary corticosteroid metabolites examined (tetrahydrocortisol, (allo)tetrahydrocortisol, tetrahydrocortisone, dehydroepiandrosterone, aetiocholanolone, tetrahydroaldosterone, and tetrahydrodeoxycortisol) are listed in Table 3. There was no significant difference in total F metabolite excretion rate (micrograms per 24 hours) between the –1889 G/T (P=0.4513) or –1859 A/G (P=0.2789) genotypes. The THS/total F ratio (index of 11ß-hydroxylase activity) was significantly higher in –1889 TT homozygotes than in GG homozygotes (P=0.024). A similar pattern was seen with the –1859 SNP, with GG homozygotes tending to have a higher ratio than AA homozygotes (P=0.056; Table 3). There was no statistically significant difference between the –1889 TT and GT groups, but the THS/F ratio remained significantly higher in the heterozygous group than the GG subjects (P=0.019). A similar pattern is seen for –1859, with no statistical difference between the GG and AG groups but a trend to a higher ratio in the heterozygous group than the AA homozygotes (P=0.066).
|
In Vitro Expression Studies
To investigate whether the altered 11ß-hydroxylase efficiency associated with the –1889 G/T and –1859 A/G SNPs in the BRIGHT population is because of an altered transcriptional response, the effects of these variants on reporter gene expression were analyzed in vitro. The impact of the –1889 G/T and –1859 A/G single base changes on gene expression using luciferase reporter gene constructs revealed no significant effect on basal expression levels. The construct containing the –1889 T and the –1859 G alleles has a significantly reduced response to stimulation with either 1 µmol/L of ACTH (P<0.001) or 10 µmol/L of forskolin (P=0.036) when compared with the contrasting allele combination (Figure 3).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The CYP11B1/2 locus is of particular interest as a key candidate region for cardiovascular disease. Previous studies have examined whether polymorphisms associated with CYP11B2 are involved in essential hypertension. We and others have reported that variation at –344 C/T is associated with increased aldosterone and increased blood pressure,9–12 but not all groups have been able to confirm this.13–16 However, we and others have found a very consistent association with good biochemical evidence of altered 11ß-hydroxylation efficiency, which draws attention to the homologous gene CYP11B1.17,18,20,21,29 The importance of this locus has been demonstrated previously in the Dahl salt-sensitive rat model of hypertension in which mutations in CYP11B1 account for the biochemical and hemodynamic abnormalities.30,31 For these reasons, in the current study, we have investigated in greater detail the pattern of variation across the region.
We now demonstrate that the overall sequence variation across the CYP11B locus is high, consistent with previous reports.32,33 Recent work has demonstrated that the –344C/T and intron Conv variants in CYP11B2 are in LD with SNPs in CYP11B1, specifically in exon 1 (225 G/A and Leu75Leu), intron 3 (2803 A/G), and intron 6 (4265 G/A).20,21 We have demonstrated previously that an increased THS excretion was correlated with haplotypes carrying the –344 T allele and that the strongest association was with the Leu75Leu SNP in CYP11B1. However, this is a conservative change and is unlikely to be functional. In the present study we have demonstrated that there is tight LD across the entire CYP11B locus. This is confirmed by the presence of relatively few common haplotypes, with 4 (each with a frequency >5%) accounting for 68% of chromosomes in the data set.
Our detailed sequencing identified several candidate variants that could account for the observed phenotypes associated previously with the –344C/T and intron Conv variants in CYP11B2. Several of these were identified in CYP11B2, and it is possible that one (or more) may contribute to the increased aldosterone levels that have been associated previously with the T/Conv haplotype.9–12 This is currently being investigated.
However, of particular interest to this study is that the –344C/T and intron Conv variants in CYP11B2 were shown to be in strong LD with several genetic variants in CYP11B1. Of the 19 variants identified in CYP11B1 that are in LD with –344 C/T and intron Conv, only 2 were located within the coding sequence, and both of these were synonymous changes (Leu75Leu and Asp82Asp). As in CYP11B2, the majority of variants identified in CYP11B1 were in intronic regions. However, 2 novel SNPs were identified in the 5' regulatory region upstream of the CYP11B1 gene at positions –1889 G/T and –1859 A/G. These may alter transcriptional regulation of the CYP11B1 gene and, therefore, contribute the observed biochemical phenotype of decreased 11ß-hydroxylation.
To investigate whether the –1889 G/T and –1859 A/G SNPs do indeed associate with altered 11ß-hydroxylation, we genotyped a subgroup from the BRIGHT hypertension study for both of these SNPs. Our data demonstrate a significant association between these SNPs and the ratio of THS/total F, the index of impaired 11ß-hydroxylase efficiency. Those subjects homozygous for the –1889 T allele showed lower 11ß-hydroxylation efficiency (increased urinary THS/total F ratio) than those homozygous for the G allele. Similarly, subjects homozygous for the –1859 G allele showed a trend toward a reduced 11ß-hydroxylation efficiency than those homozygous for the A allele, although this did not quite reach statistical significance. As mentioned previously, it is these alleles (–1889 T and –1859 G) that are in LD with the CYP11B2 T/Conv haplotype. Importantly, there was no difference in urinary excretion of total cortisol metabolites between the 2 genotype groups for each SNP.
The effects of the –1889 G/T and –1859 A/G SNPs on gene transcription were tested in vitro using a luciferase reporter gene system. Compared with Wt (ie, –1889 G and –1859 A), constructs containing the –1889 T and –1859 G alleles reduced reporter gene activity by 50% in response to the agonists ACTH and the adenylate cyclase agonist forskolin, indicating decreased transcription. These data strongly support the theory that the reduced 11ß-hydroxylation associated previously with the T/Conv haplotype in CYP11B2 is accounted for by variants in CYP11B1, such as –1889 T and –1859 G. The is one of the first studies in humans to identify novel genetic variants in a candidate gene for hypertension, which not only associate with an intermediate phenotype but have also been shown to have functional effects on gene transcription in vitro.
Perspectives
Evidence of a slightly reduced 11ß-hydroxylase efficiency is a consistent feature of subjects with essential hypertension compared with normotensive control subjects.34–36 This study demonstrates that the –1889 G/T and –1859 A/G SNPs in CYP11B1, which associate with reduced 11ß-hydroxylase efficiency, are in LD with those variants in CYP11B2 that associate with higher aldosterone levels. How the 2 effects are related is currently being investigated.
|
Acknowledgments |
|---|
Sources of Funding
This study was supported by funding from the Medical Research Council (N.J.S., J.M.C.C., and E.D.) and the British Heart Foundation (S.M.M., J.M.C.C., and E.D.).
Disclosures
None.
Received June 13, 2006; first decision July 11, 2006; accepted October 3, 2006.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004; 351: 33–41.
2. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet. 1999; 353: 40.[Medline] [Order article via Infotrieve]
3. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994; 21: 315–318.[Medline] [Order article via Infotrieve]
4. Loh KC, Koay ES, Khaw MC, Emmaunel SC, Young WFJ. Prevelance of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000; 85: 2854–2859.
5. Fardella CE, Mosso L, Gomez-Sanchez CE, Cortez P, Soto J, Gomez L Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary aldosteronism in essential hypertensives; prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab. 2000; 85: 1863–1867.
6. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J. 2000; 90: 394–400.[Medline] [Order article via Infotrieve]
7. Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11 beta- hydroxylase (P-450(11) beta). J Biol Chem. 1989; 264: 20961–20967.
8. White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res. 1995; 21: 437–442.[Medline] [Order article via Infotrieve]
9. Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, Anderson NH, Fraser R, Connell JMC. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension. 1999; 33: 703–707.
10. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L, Soubrier F. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension. 1998; 32: 198–204.
11. Lim PO, MacDonald TM, Holloway CD, Friel EC, Anderson NH, Dow E, Jung RT, Davies E, Fraser R, Connell JMC. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone to renin ratio. J Clin Endocrinol Metab. 2002; 87: 4398–4402.
12. Paillard F, Chansel D, Brand E, Benetos A, Thomas F, Czekalski S, Ardaillou R, Soubrier F. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension. 1999; 34: 423–429.
13. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H, White PC. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation. 1998; 97: 569–575.
14. Tsujita Y, Iwai N, Katsuya T, Higaki J, Ogihara T, Tamaki S, Kinoshita M, Mannami T, Ogata J, Baba S. Lack of association between genetic polymorphism of CYP11B2 and hypertension in Japanese: the Suita study. Hypertens Res. 2001; 24: 105–109.[CrossRef][Medline] [Order article via Infotrieve]
15. Pojoga L, Gautier S, Blanc H, Guyene TT, Poirier O, Cambien F, Benetos. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens. 1998; 11: 856–860.[CrossRef][Medline] [Order article via Infotrieve]
16. Schunkert H, Hengstenberg C, Holmer SR, Broeckel U, Luchner A, Muscholl MW, Kürzinger S, Döring A, Hense H-W, Riegger GAJ. Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Circulation. 1999; 99: 2255–2260.
17. Davies E, Holloway CD, Ingram MC, Friel EC, Inglis GC, Swan L, Hillis WS, Fraser R, Connell JMC. An influence of variation in the aldosterone synthase gene (CYP11B2) on corticosteroid responses to ACTH in normal human subjects. Clin Endocrinol (Oxf). 2001; 54: 813–817.[CrossRef][Medline] [Order article via Infotrieve]
18. Hautanena A, Lankinen L, Kupari M, Janne OA, Adlercreutz H, Nikkila H, White PC. Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males. J Intern Med. 1998; 244: 11–18.[CrossRef][Medline] [Order article via Infotrieve]
19. Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE. Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1. J Mol Endocrinol. 2002; 28: 125–135.[Abstract]
20. Ganapathipillai S, Laval G, Hoffmann IS, Castejon AM, Nicod J, Dick B, Frey FJ, Frey BM, Cubeddu LX, Ferrari P. CYP11B2-CYP11B1 haplotypes associated with decreased 11 beta-hydroxylase activity. J Clin Endocrinol Metab. 2005; 90: 1220–1225.
21. Keavney B, Mayosi B, Gaukrodger N, Imrie H, Baker M, Fraser R, Ingram M, Watkins H, Farrall M, Davies E, Connell J. Genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor (11-deoxycortisol) urinary metabolite excretion. J Clin Endocrinol Metab. 2005; 90: 1072–1077.
22. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JMC. Cortisol effects on body mass, blood pressure and cholesterol in the general population. Hypertension. 1999; 33: 1364–1368.
23. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, Benjamin N, Webster J, Ratcliffe P, O’Shea S, Papp J, Taylor E, Dobson R, Knight J, Newhouse S, Hooper J, Lee W, Brain N, Clayton D, Lathrop GM, Farrall M, Connell J. Genome-wide mapping of human loci for essential hypertension. Lancet. 2003; 361: 2118–2123.[CrossRef][Medline] [Order article via Infotrieve]
24. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68: 978–989.[CrossRef][Medline] [Order article via Infotrieve]
25. Shackleton CH. Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J Steroid Biochem Mol Biol. 1993; 45: 127–140.[CrossRef][Medline] [Order article via Infotrieve]
26. Fisher A, Fraser R, Connell JMC, Davies E. Amino acid 147 of human aldosterone synthase and 11ß-hydroxylase plays a key role in 11ß-hydroxylation. J Clin Endocrinol Metab. 2000; 85: 1261–1266.
27. Fardella CE, Hum DW, Rodriguez H, Zhang G, Barry FL, Ilicki A, Bloch CA, Miller WL. Gene conversion in the CYP11B2 gene encoding P450c11AS is associated with, but does not cause, the syndrome of corticosterone methyloxidase II deficiency. J Clin Endocrinol Metab. 1996; 81: 321–326.[Abstract]
28. Portrat-Doyen S, Tourniaire J, Richard O, Mulatero P, Aupetit-Faisant B, Curnow KM, Pascoe L, Morel Y. Isolated aldosterone synthase deficiency caused by simultaneous E198D and V386A mutations in the CYP11B2 gene. J Clin Endocrinol Metab. 1998; 83: 4156–4161.
29. Kennon B, Ingram MC, Friel EC, Anderson NH, MacKenzie SM, Davies E, Shakerdi L, Wallace AM, Fraser R, Connell JM. Aldosterone synthase gene variation and adrenocortical response to sodium status, angiotensin II and ACTH in normal male subjects. Clin Endocrinol (Oxf). 2004; 61: 174–181.[CrossRef][Medline] [Order article via Infotrieve]
30. Cicila G, Rapp JR, Wang J-M, St Lezin E, Ng S, Kurtz TW. Linkage of 11ß-hydroxylase mutations with altered steroid biosynthesis and blood pressure in Dahl rat. Nat Genet. 1993; 3: 346–353.[CrossRef][Medline] [Order article via Infotrieve]
31. Cicila GT, Garrett MR, Lee SJ, Liu J, Dene H, Rapp JR. High-resolution mapping of the blood pressure QTL on chromosome 7 using Dahl rat congenic strains. Genomics. 2001; 72: 51–60.[CrossRef][Medline] [Order article via Infotrieve]
32. Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet. 1999; 22: 239–247.[CrossRef][Medline] [Order article via Infotrieve]
33. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999; 22: 231–238.[CrossRef][Medline] [Order article via Infotrieve]
34. Connell JMC, Jamieson A, Davies E, Ingram MC, Soro A, Fraser R. 11Beta-hydroxylase activity in glucocorticoid suppressible hyperaldosteronism: lessons for essential hypertension? Endocr Res. 1996; 22: 691–700.[Medline] [Order article via Infotrieve]
35. de Simone G, Tommaselli A, Rossi R, Valentino R, Lauria R, Scopacasa F, Lombardi G. Partial deficiency of adrenal 11ß-hydroxylase - a possible cause of primary hypertension. Hypertension. 1985; 7: 613–618.
36. Honda M, Nowaczynski W, Guthrie GP Jr, Messeril FH, Tolis G, Kuchel O, Genest J. Response of several adrenal steroids to ACTH stimulation in essential hypertension. J Clin Endocrinol Metab. 1977; 44: 264–272.
This article has been cited by other articles:
 |
|
 |
|
  S. Alvarez-Madrazo, S. Padmanabhan, B. M. Mayosi, H. Watkins, P. Avery, A. M. Wallace, R. Fraser, E. Davies, B. Keavney, and J. M. Connell Familial and Phenotypic Associations of the Aldosterone Renin Ratio J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4324 - 4333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Sookoian, T F Gianotti, and C J Pirola Role of the C-344T aldosterone synthase gene variant in left ventricular mass and left ventricular structure-related phenotypes Heart, July 1, 2008; 94(7): 903 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-a. B. Shih and D. T. O'Connor Hereditary Determinants of Human Hypertension: Strategies in the Setting of Genetic Complexity Hypertension, June 1, 2008; 51(6): 1456 - 1464. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. C. Connell, S. M. MacKenzie, E. M. Freel, R. Fraser, and E. Davies A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function Endocr. Rev., April 1, 2008; 29(2): 133 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Deng Genetic basis of polygenic hypertension Hum. Mol. Genet., October 15, 2007; 16(R2): R195 - R202. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||